Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS

International NETwork for training and innovations in THErapeutic RADiation

Projektbeschreibung

Internationales Ausbildungsnetzwerk verbessert Strahlentherapien auf Basis biologischer Faktoren

Gesunde Zellen können DNA-Schäden viel besser reparieren als kranke Zellen. Eine gezielte Bestrahlung muss also bei einer Dosis erfolgen, die Krebszellen abtötet, ohne gesunde Zellen zu schädigen. Bei dieser Art von Behandlung wird der Tumor mit ionisierender Strahlung bestrahlt und die DNA der Krebszellen so stark geschädigt, dass der Zelltod eintritt. Nun sollen strahleninduzierte Veränderungen an Tumoren, Mikroumgebung und Immunsystem genauer erforscht werden, um Strahlentherapien wirksamer zu machen. Mit dem Projekt THERADNET, das Strahlenbiologen aus sechs Ländern zusammenbringt, soll die kritische Masse erreicht werden, um neue Erkenntnisse und Innovationen in der Strahlentherapie zu fördern. Dies soll den Weg für einen effektiveren Einsatz dieser gängigen und wirksamen Waffe gegen die meisten Krebsarten ebnen.

Ziel

Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training.
The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care.
Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.

Koordinator

UNIVERSITAT ZURICH
Netto-EU-Beitrag
€ 562 553,28
Adresse
RAMISTRASSE 71
8006 Zurich
Schweiz

Auf der Karte ansehen

Region
Schweiz/Suisse/Svizzera Zürich Zürich
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 562 553,28

Beteiligte (7)